MEDICAL EXPRESS REPORTS
IMPACT FACTOR:12.45 ISSN:1469-1981




# CLINICAL AND LABORATORY FACTORS AFFECTING THE EFFECTIVENESS OF ASSISTED REPRODUCTIVE TECHNOLOGIES IN INFERTILITY TREATMENT

**Abdujabborova Sevinch Shavkat qizi**
*Tashkent International University of Kimyo, Namangan Branch (KIUT), Faculty of General Medicine, 3rd-year student,*
*+998935821305 / abdujabborova425@gmail.com*
**Abdurahmonova Ziyoda Abdulla qizi**
*Tashkent International University of Kimyo, Namangan Branch (KIUT), Faculty of General Medicine, 3rd-year student,*
*+998933205231 / ziyodaabdurahmonova79@gmail.com*
***Scientific supervisor:*** **Kamalova Gulnora Gulyamovna**
*PhD, Acting Assoc. Prof., Tashkent International University of Kimyo, Namangan Branch Namangan, Uzbekistan*

**ARTICLE INFO:**

*Received:29.10.2026*
*Revised: 30.10.2026*
*Accepted:31.10.2026*

**KEY WORDS:**

*Infertility, assisted reproductive technologies, in vitro fertilization, intracytoplasmic sperm injection, ovarian reserve, anti-Müllerian hormone, antral follicle count, oocyte quality, sperm quality, embryo development, endometrial receptivity, ovarian stimulation,*

**ABSTRACT**

*Infertility is a major reproductive health concern that affects individuals and couples worldwide and may result from female, male, combined, or unexplained reproductive disorders. Assisted reproductive technologies (ART), particularly in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI), have significantly expanded the possibilities of achieving pregnancy in patients with different causes of infertility. However, treatment outcomes vary considerably, even among patients receiving similar treatment protocols. This variability reflects the interaction of clinical characteristics, endocrine function, ovarian reserve, gamete quality, embryo developmental competence, endometrial conditions, and laboratory performance. Understanding these determinants is essential for improving treatment selection, optimizing safety, and establishing realistic expectations regarding reproductive outcomes. The aim of this article is to analyze the clinical and laboratory factors influencing the*

*embryology laboratory, cumulative live birth rate, reproductive medicine.*

*effectiveness of assisted reproductive technologies and to identify evidence-based approaches for improving infertility management. The study was designed as a narrative review of international clinical guidelines, scientific publications, and relevant regulatory documents from Uzbekistan. The analysis focused on female age, anti-Müllerian hormone (AMH), antral follicle count (AFC), endocrine and metabolic disorders, uterine and tubal abnormalities, male reproductive characteristics, semen parameters, oocyte competence, embryo morphology, blastocyst development, cryopreservation, and embryology laboratory quality indicators. The reviewed evidence indicates that female age is a major determinant of reproductive prognosis because of its association with oocyte competence and embryo chromosomal abnormalities. AMH and AFC are valuable predictors of ovarian response to stimulation, but they should not be interpreted as independent predictors of live birth. Male reproductive factors influence fertilization and may affect subsequent embryo development, while uterine and tubal abnormalities can compromise implantation or pregnancy maintenance. Laboratory conditions, including temperature and pH stability, culture media, equipment performance, gamete handling, and cryopreservation procedures, are also important components of treatment quality. The analysis supports an individualized approach integrating comprehensive clinical assessment, appropriate ovarian stimulation, targeted investigation of male and female reproductive factors, standardized embryological procedures, and continuous laboratory quality assurance. Treatment effectiveness should be evaluated using clearly defined outcomes, particularly cumulative live birth rate, while considering safety and patient-centered outcomes. In conclusion, the optimization of ART requires coordinated clinical and laboratory management rather than reliance on a single biomarker or procedural technique.*

**Introduction:** Infertility is a reproductive health condition characterized by the inability to achieve pregnancy after a specified period of regular, unprotected sexual intercourse or by an

established impairment of reproductive capacity. It represents an important medical and social problem because it can affect psychological well-being, family relationships, quality of life, and access to reproductive healthcare. The World Health Organization emphasizes that infertility prevention, diagnosis, and treatment should form an integral part of comprehensive reproductive health services [1]. The causes of infertility are heterogeneous and may involve female reproductive dysfunction, male-factor infertility, combined abnormalities, or unexplained conditions. Female factors include ovulatory disorders, diminished ovarian reserve, age-related decline in oocyte competence, endometriosis, tubal damage, and uterine abnormalities. Male factors may include impaired sperm concentration, motility or morphology, abnormalities of spermatogenesis, reproductive tract disorders, and ejaculatory dysfunction. In many couples, several contributing factors coexist, making individualized diagnostic assessment essential. Assisted reproductive technologies have transformed infertility treatment by enabling fertilization and early embryonic development under controlled laboratory conditions. In vitro fertilization involves ovarian stimulation when indicated, oocyte retrieval, fertilization, embryo culture, and transfer of an embryo into the uterus. Intracytoplasmic sperm injection is a specialized fertilization method in which a single spermatozoon is injected directly into an oocyte. The choice of technique depends on the clinical indication, reproductive history, semen characteristics, and previous treatment outcomes. Despite advances in reproductive medicine, successful fertilization does not guarantee embryo implantation, clinical pregnancy, or live birth. Reproductive success depends on a sequence of interrelated processes, including follicular development, oocyte maturation, fertilization, embryo development, endometrial interaction, implantation, placentation, and pregnancy maintenance. Disturbances at any stage may reduce the probability of achieving the desired outcome. The effectiveness of ART should therefore not be assessed exclusively through the number of retrieved oocytes, fertilization rate, or proportion of embryos reaching the blastocyst stage. These parameters provide useful information about individual stages of treatment but do not independently establish the probability of live birth. Cumulative live birth rate, which accounts for relevant embryo transfers arising from a treatment episode, offers a broader assessment of reproductive outcomes when clearly defined and appropriately followed. Recent international recommendations emphasize evidence-based infertility management, individualized ovarian stimulation, patient safety, and the evaluation of clinically meaningful outcomes. The WHO guideline published in 2025 provides recommendations for infertility prevention, diagnosis, and treatment, while the European Society of Human Reproduction and Embryology (ESHRE) updated its ovarian stimulation guideline in 2025 [1, 2]. These recommendations reinforce the need to distinguish predictors of ovarian response from predictors of pregnancy and live birth. In Uzbekistan, the regulation of assisted reproductive technologies is supported by national legislation and healthcare regulations. The Ministry of Health's Order No. 106 of 14 January 2020, registered on 6 February 2020 under registration number 3217, established regulations governing the use of

assisted reproductive technologies. In addition, Presidential Resolution No. PQ-296 of 8 September 2023 addressed maternal and child health protection and the strengthening of reproductive health services [8, 9]. The relevance of the present topic lies in the need to integrate clinical evaluation, laboratory diagnostics, individualized treatment protocols, and standardized embryological procedures to improve the quality and safety of infertility care. The aim of this article is to analyze the clinical and laboratory factors associated with the effectiveness of assisted reproductive technologies in infertility treatment and to formulate practical recommendations based on contemporary scientific evidence. The objectives are to identify major female and male predictors of ART outcomes; assess the clinical significance of ovarian reserve and endocrine parameters; examine the contribution of gamete quality and embryo development; analyze laboratory-related determinants of treatment quality; and outline approaches to improving treatment planning and outcome assessment.

**Literature review:** Female age is one of the most important determinants of reproductive prognosis. As age increases, the quantity of available oocytes generally decreases, while the likelihood of chromosomal abnormalities in oocytes and embryos increases. These changes can contribute to lower implantation probability, a greater risk of pregnancy loss, and reduced live birth rates. Although individual reproductive trajectories differ, age remains essential when interpreting diagnostic findings and counseling patients about treatment expectations [3]. Ovarian reserve refers primarily to the remaining pool of recruitable follicles. Anti-Müllerian hormone and antral follicle count are commonly used to estimate ovarian reserve and predict ovarian response to stimulation. AMH is produced by granulosa cells of developing follicles, whereas AFC is assessed by transvaginal ultrasonography. These markers help clinicians anticipate the likely number of follicles responding to stimulation and identify patients who may experience a low or excessive ovarian response. However, ovarian reserve markers are not direct measurements of oocyte chromosomal competence and should not be used independently to predict live birth. A low AMH concentration may indicate a reduced expected ovarian response but does not establish that pregnancy is impossible. Similarly, a high AMH concentration does not guarantee implantation or successful delivery [3, 4]. The American Society for Reproductive Medicine recommends interpreting ovarian reserve tests alongside age, reproductive history, clinical diagnosis, and previous treatment response. Their primary role is to guide treatment planning and counseling rather than to serve as isolated measures of fertility potential [3].

Endocrine disorders may interfere with ovulation, ovarian response, endometrial development, and pregnancy maintenance. Polycystic ovary syndrome is associated with ovulatory dysfunction and may coexist with insulin resistance and metabolic abnormalities. Patients with this condition may demonstrate a strong response to ovarian stimulation and require individualized strategies to reduce the risk of ovarian hyperstimulation syndrome. Thyroid dysfunction and hyperprolactinemia may also affect reproductive function in selected

patients. The significance of these abnormalities depends on their severity, associated clinical manifestations, and underlying cause. Therefore, endocrine investigations should be guided by clinical indications rather than indiscriminate testing of all available hormonal markers. Body mass index is another relevant clinical parameter. Both low and high BMI may be associated with reproductive and pregnancy-related complications, although the magnitude of the association varies according to age, metabolic status, infertility diagnosis, and treatment protocol. BMI should be considered as one element of a comprehensive assessment rather than as an independent determinant of treatment success. The purpose of pre-treatment assessment is to identify clinically significant and potentially modifiable conditions that may compromise treatment safety or reproductive outcomes. Appropriate management of relevant endocrine and metabolic disorders can improve general health and support safer fertility treatment.

The uterine environment is essential for implantation and the continuation of pregnancy. Structural abnormalities, including endometrial polyps, submucosal fibroids, intrauterine adhesions, and selected congenital uterine anomalies, may affect reproductive outcomes depending on their type, location, and severity. Hydrosalpinx is particularly relevant in patients with tubal-factor infertility because fluid associated with a damaged fallopian tube may adversely affect implantation. Identification of clinically significant tubal disease can influence the choice and timing of treatment. Endometrial receptivity involves coordinated molecular, cellular, and physiological processes that permit embryo attachment and implantation. Endometrial development is influenced by hormonal exposure and uterine conditions. However, endometrial thickness alone is an imperfect predictor of reproductive success and should not be interpreted as a definitive measure of receptivity. Diagnostic investigations should be selected according to the patient's medical history, ultrasound findings, previous treatment outcomes, and established clinical indications. Routine additional testing is not necessarily beneficial for every patient, particularly when evidence of clinical utility remains limited.

Male-factor infertility contributes substantially to the overall burden of infertility and should be assessed alongside female reproductive factors. Semen analysis is a fundamental component of the initial evaluation. Relevant parameters include semen volume, sperm concentration, total sperm number, motility, and morphology. Abnormal semen parameters may reflect disturbances in spermatogenesis, endocrine dysfunction, reproductive tract abnormalities, systemic illness, genetic conditions, or environmental exposures. Because semen characteristics may vary between samples, repeat testing and further investigation may be required when clinically appropriate. ICSI has expanded treatment options for selected forms of male-factor infertility and previous fertilization failure. Nevertheless, this technique does not eliminate all biological limitations associated with sperm or oocyte quality. Successful fertilization does not necessarily ensure normal embryo development or successful implantation. Additional investigations, including sperm DNA fragmentation testing, may be considered in selected clinical situations. However, such tests should not be incorporated automatically into every infertility assessment

because their indications and effects on treatment decisions vary. Established diagnostic methods should remain the foundation of evaluation, with specialized investigations guided by clinical findings [5].Oocyte competence refers to the ability of an oocyte to undergo normal maturation, support fertilization, and sustain early embryonic development. It is influenced by age, ovarian physiology, stimulation response, and biological characteristics that cannot always be measured directly using routine clinical tests. The number of retrieved oocytes is an important intermediate outcome of IVF. Nevertheless, a higher oocyte yield does not necessarily produce a proportional increase in live birth probability. Oocyte maturity, fertilization, embryo development, and the number of embryos available for transfer also influence the overall outcome. Embryo assessment traditionally relies on morphological criteria, including cell number, fragmentation, symmetry, and blastocyst development. These characteristics help embryologists rank embryos for transfer or cryopreservation. However, morphology cannot completely determine chromosomal status or developmental competence. Blastocyst culture permits assessment at a later developmental stage and may assist embryo selection. Its suitability depends on the number and quality of available embryos, laboratory performance, patient prognosis, and clinical strategy. Extended culture should not automatically be considered superior in every case. Preimplantation genetic testing for aneuploidy may be considered in selected clinical contexts. Nevertheless, it should not be treated as a universal method for improving cumulative live birth rates across all IVF patients. Potential benefits, limitations, inconclusive findings, and the implications of embryo biopsy require appropriate counseling and adherence to current evidence-based recommendations.

The embryology laboratory is a critical component of ART because oocytes, spermatozoa, and embryos are exposed to controlled external conditions during handling, fertilization, culture, and cryopreservation. Laboratory performance depends on environmental stability, culture media, equipment reliability, staff competency, and standardized procedures. Temperature fluctuations, inappropriate pH, changes in gas composition, contamination, and excessive exposure to external conditions may adversely affect embryo development. Laboratories therefore require validated equipment, regular calibration, preventive maintenance, documented procedures, and continuous quality monitoring. Quality assurance should include the systematic recording of relevant indicators, such as fertilization rates, embryo development, blastocyst formation, cryosurvival, and other measures appropriate to the laboratory's patient population. These indicators must be interpreted carefully because patient characteristics and clinical protocols may influence outcomes independently of laboratory performance [6]. Cryopreservation, particularly vitrification, has expanded the possibility of preserving embryos for subsequent transfer. Successful cryopreservation requires validated protocols, appropriate handling, and reliable warming procedures. Laboratory effectiveness is therefore best understood as the combination of technical performance, biological outcomes, safety, and continuous quality improvement.

Controlled ovarian stimulation aims to recruit multiple follicles while maintaining patient safety and obtaining oocytes suitable for fertilization. The selection of a stimulation protocol depends on ovarian reserve, anticipated response, age, diagnosis, previous treatment outcomes, and the risk of complications. The ESHRE guideline updated in 2025 recommends AMH or AFC for predicting high and low ovarian responses. However, these markers are not recommended as independent predictors of pregnancy or live birth [2]. This distinction is important because ovarian response and reproductive success represent different stages of treatment. Ovarian hyperstimulation syndrome is a potentially serious complication in susceptible patients. Prevention requires individualized risk assessment, appropriate protocol selection, monitoring, and evidence-based preventive measures when indicated. The objective of treatment is not simply to maximize the number of retrieved oocytes, but to balance reproductive effectiveness, safety, and the individual patient's circumstances. This principle is particularly important when interpreting outcomes across different clinics and patient populations.

Uzbekistan has established a regulatory framework governing the use of assisted reproductive technologies. The Ministry of Health's Order No. 106 of 14 January 2020, registered as No. 3217, defines the procedures for the use of ART and includes requirements relating to patient consent and the provision of reproductive services by appropriately authorized medical organizations [8]. Presidential Resolution No. PQ-296 of 8 September 2023 addresses the protection of maternal and child health and the strengthening of reproductive health services. It also provides a framework for developing modern clinical protocols and improving the organization of reproductive healthcare [9]. These national measures are relevant to the implementation of evidence-based infertility treatment, although the effectiveness of specific clinical and laboratory interventions must continue to be evaluated using appropriate clinical outcome data.

**Research materials and methods:** The present article was designed as a narrative literature review examining clinical and laboratory factors that influence the effectiveness of assisted reproductive technologies in infertility treatment. The evidence base consisted of international clinical guidelines, peer-reviewed scientific publications, established reviews, and relevant national regulatory documents. Priority was given to sources addressing infertility assessment, ovarian reserve, ovarian stimulation, male reproductive factors, embryo development, laboratory performance, and reproductive outcomes. The main sources included the WHO guideline on infertility prevention, diagnosis, and treatment published in 2025; the ESHRE guideline on ovarian stimulation for IVF/ICSI updated in 2025; recommendations of the American Society for Reproductive Medicine; scientific studies on ovarian reserve and ART outcomes; and publications concerning laboratory quality indicators. National documents regulating assisted reproductive technologies in Uzbekistan were also reviewed.

**The literature was analyzed according to five principal domains:**

1. Clinical determinants, including age, reproductive history, ovarian reserve, endocrine disorders, and uterine or tubal abnormalities.
2. Male reproductive factors, including semen parameters, indications for ICSI, and selected additional investigations.
3. Embryological determinants, including oocyte maturity, fertilization, embryo morphology, blastocyst development, and cryopreservation.
4. Laboratory determinants, including environmental control, culture conditions, equipment performance, and quality assurance.
5. Treatment outcomes, including ovarian response, fertilization, implantation, clinical pregnancy, pregnancy loss, cumulative live birth, and treatment-related complications.

A descriptive and comparative approach was used to summarize the clinical relevance, potential benefits, and limitations of the identified factors. Particular attention was paid to distinguishing intermediate laboratory outcomes from final clinical outcomes and predictors of ovarian response from predictors of live birth. Because the article did not involve recruitment of a new patient cohort, original laboratory experiments, or access to a clinical database, no original statistical analysis was performed. The findings are therefore presented as a qualitative synthesis of existing evidence rather than as results from a clinical trial or observational study.

**Research results:** The literature review identified several interconnected categories of factors influencing ART effectiveness. These included patient-related clinical characteristics, ovarian response, gamete quality, embryological development, laboratory performance, and the definition of treatment success.

Female age emerged as a major prognostic factor because of its association with oocyte competence, embryo chromosomal status, and reproductive potential. Ovarian reserve markers provide complementary information by estimating the likely response to stimulation, but they do not replace age-based prognostic assessment. AMH and AFC were identified as useful predictors of ovarian response. Their primary value lies in helping clinicians anticipate the likely number of recruitable follicles and select a suitable stimulation strategy. Neither marker should be interpreted as a direct measurement of embryo quality or as an independent guarantee of pregnancy. Endocrine and metabolic conditions were also identified as relevant clinical considerations. Ovulatory dysfunction, thyroid disease, hyperprolactinemia, and clinically significant metabolic abnormalities may require investigation and management according to individual findings. Their influence varies with the underlying diagnosis and severity. Uterine and tubal abnormalities may affect implantation or pregnancy maintenance. Their clinical significance depends on the nature, severity, and anatomical location of the abnormality. Targeted imaging and additional diagnostic procedures should therefore be selected according to medical history and initial findings.

The reviewed evidence supports the assessment of both partners rather than focusing exclusively on female reproductive parameters. Semen analysis provides essential information about sperm concentration, motility, morphology, and other characteristics relevant to treatment planning. The choice between conventional IVF and ICSI should be based on clinical indications, semen characteristics, and previous fertilization history. Although ICSI can overcome selected barriers to fertilization, it does not remove all biological limitations associated with gamete competence or subsequent embryo development. Oocyte maturity, fertilization outcomes, and embryo developmental progression are useful intermediate indicators. However, they should be interpreted within the context of patient characteristics and the overall treatment pathway.

Embryo morphology and developmental stage provide useful information for embryo selection. Nevertheless, morphological grading cannot completely predict chromosomal status, implantation, or live birth. The literature also emphasizes the importance of standardized laboratory conditions. Stable temperature, appropriate pH, validated culture systems, effective contamination prevention, and consistent cryopreservation procedures are necessary for maintaining laboratory quality. Laboratory performance should be assessed using several indicators rather than a single measure. Fertilization and blastocyst formation rates provide information about intermediate stages, whereas live birth outcomes reflect the combined influence of clinical, biological, and laboratory factors.

The review demonstrated that the interpretation of ART effectiveness depends on the selected outcome measure. Fertilization rate, implantation rate, clinical pregnancy rate, and live birth rate represent different stages of the reproductive process and should not be used interchangeably. Cumulative live birth rate is particularly informative when several embryo transfers arise from one treatment episode. However, comparisons between clinics or protocols require clearly defined denominators, consistent follow-up periods, and appropriate consideration of differences in patient characteristics. Individualized ovarian stimulation, management of identified reproductive disorders, careful embryo assessment, and laboratory quality assurance were identified as complementary components of a comprehensive treatment strategy. The national regulatory framework in Uzbekistan provides a basis for the organized use of ART. However, the effectiveness of specific clinical and laboratory approaches in the national population requires continued evaluation through appropriately designed clinical studies. Overall, the evidence supports a multidimensional model of ART effectiveness rather than reliance on a single biomarker, laboratory parameter, or procedural technique.

**Discussion:** The effectiveness of assisted reproductive technologies is determined by the interaction of clinical characteristics, the underlying cause of infertility, treatment selection, embryological development, and laboratory performance. This complexity explains why similar treatment protocols may produce different outcomes in patients with different reproductive profiles. Female age deserves particular attention because it provides important prognostic

information that cannot be replaced by ovarian reserve testing. AMH and AFC are valuable for predicting ovarian response, but they do not directly measure chromosomal competence. A patient may have an adequate ovarian response while still having a reduced probability of live birth because of age-related changes in oocyte quality. Conversely, a low predicted response does not necessarily exclude the possibility of pregnancy. These distinctions have practical implications for patient counseling. Clinicians should explain the difference between the expected number of oocytes, the probability of obtaining transferable embryos, and the likelihood of achieving a live birth. This approach helps prevent the misinterpretation of laboratory measurements as definitive predictions of reproductive success. The role of male reproductive factors should also be emphasized. Although ART has created effective options for selected forms of male-factor infertility, advanced laboratory techniques cannot compensate for every underlying biological limitation. Comprehensive evaluation of both partners may identify conditions that influence treatment selection or indicate the need for additional investigations. Laboratory quality is another major determinant of treatment consistency. Reproductive laboratories operate within narrow environmental requirements, and deviations may affect gamete or embryo development. Standard operating procedures, equipment validation, staff training, quality-control systems, and systematic review of laboratory outcomes are therefore essential. However, laboratory indicators must be interpreted in the context of patient characteristics and treatment protocols. A difference in fertilization or blastocyst formation rates does not automatically establish a difference in laboratory quality because clinical case mix may contribute to observed variation. Embryo morphology remains useful, but it is not a complete measure of developmental potential. The introduction of additional technologies should be guided by evidence of clinical benefit rather than technological availability alone. Preimplantation genetic testing may be appropriate in selected indications, but routine use across all patient groups cannot be assumed to improve cumulative live birth outcomes. The choice of outcome measure is equally important. High fertilization or blastocyst formation rates do not automatically translate into high cumulative live birth rates. Studies should distinguish between outcomes per initiated cycle, per oocyte retrieval, per embryo transfer, and per patient over a defined period. Without these distinctions, apparent differences in effectiveness may reflect variations in reporting rather than genuine differences in clinical performance. Individualized treatment should integrate clinical evaluation, ovarian response prediction, appropriate stimulation protocols, assessment of uterine and male factors, and laboratory quality assurance. This approach is consistent with contemporary international recommendations emphasizing patient-specific decision-making and treatment safety [1, 2]. The national context is also important. Uzbekistan's regulations establish a framework for the provision of assisted reproductive technologies and the protection of reproductive rights. Effective implementation requires qualified specialists, reliable laboratory infrastructure, appropriate patient selection, informed consent, and monitoring of clinically meaningful outcomes [8, 9]. Several limitations

should be acknowledged. First, this article is a narrative review rather than a systematic review with a reproducible database search and formal risk-of-bias assessment. Second, the included sources differ in methodology, populations, treatment protocols, and outcome definitions. Third, the review cannot establish the independent causal contribution of each factor or quantify its effect in a particular patient population. Future research should prioritize prospective multicenter studies using standardized definitions of ART outcomes. Models integrating clinical variables, ovarian reserve markers, semen characteristics, embryo development, and laboratory indicators may improve individualized prognosis. Such models should be externally validated before incorporation into routine clinical decision-making.

**Conclusion and practical recommendations:** The effectiveness of assisted reproductive technologies in infertility treatment depends on the combined influence of clinical, endocrine, anatomical, male reproductive, embryological, and laboratory factors. No single parameter is sufficient to predict the entire reproductive outcome, and treatment decisions should be based on a comprehensive assessment of the individual patient or couple. Female age remains a major prognostic factor because of its association with oocyte competence and embryo chromosomal status. AMH and AFC are valuable for predicting ovarian response, but they should not be interpreted as independent predictors of live birth. Male reproductive assessment, including semen analysis, is necessary for identifying contributing factors and selecting an appropriate fertilization strategy. Uterine and tubal abnormalities should be investigated when clinically indicated, while endocrine and metabolic disorders should be managed according to established recommendations. Laboratory quality assurance is essential for maintaining stable conditions during gamete handling, fertilization, embryo culture, and cryopreservation. Embryo morphology and developmental stage provide useful selection criteria but cannot fully determine implantation or live birth potential.

**The following practical recommendations are proposed:**

1. Conduct a comprehensive infertility assessment that includes reproductive history, female age, ovulatory function, clinically indicated endocrine investigations, ovarian reserve assessment, uterine and tubal evaluation, and simultaneous assessment of male reproductive factors.
2. Interpret AMH and AFC primarily as indicators of expected ovarian response. Avoid using these measurements alone to determine the probability of live birth or to exclude patients from treatment.
3. Individualize ovarian stimulation according to the patient's clinical profile, expected response, previous treatment outcomes, and risk of ovarian hyperstimulation syndrome.
4. Perform semen analysis as part of the initial evaluation and select conventional IVF or ICSI according to established clinical indications rather than using ICSI automatically in every treatment cycle.

5. Investigate uterine and tubal abnormalities when supported by medical history, imaging findings, or previous treatment outcomes. Avoid unnecessary invasive investigations without a clear clinical indication.
6. Maintain standardized embryology laboratory procedures, including environmental monitoring, equipment calibration, staff training, documentation, contamination prevention, and validated cryopreservation protocols.
7. Interpret embryo morphology alongside developmental stage and clinical context. Explain that favorable morphological grading does not guarantee implantation or live birth.
8. Use additional technologies, including preimplantation genetic testing, only when their indications and potential benefits are supported by current evidence and appropriate patient counseling.
9. Evaluate ART effectiveness using clearly defined outcomes, particularly cumulative live birth rate, while also monitoring treatment safety, pregnancy loss, multiple pregnancy, and other clinically relevant outcomes.
10. Develop prospective research and quality-improvement programs to assess the combined predictive value of clinical and laboratory factors in different patient populations, including patients receiving ART in Uzbekistan.

In conclusion, improving ART outcomes requires an integrated strategy combining individualized clinical management, appropriate laboratory techniques, evidence-based embryo selection, and continuous quality improvement. The most effective approach is not necessarily the one that maximizes a single laboratory parameter, but the one that improves meaningful reproductive outcomes while maintaining patient safety and providing realistic, evidence-based counseling.

## REFERENCES:

1. World Health Organization. Guideline for the Prevention, Diagnosis and Treatment of Infertility. Geneva: World Health Organization; 2025. 262 p.
2. ESHRE Guideline Group on Ovarian Stimulation, Ata B., Bosch E., Broer S., Griesinger G., Grynberg M., et al. ESHRE guideline: ovarian stimulation for IVF/ICSI: an update in 2025. Human Reproduction. 2026;41(4):498–514. Oxford University Press.
3. Practice Committee of the American Society for Reproductive Medicine. Fertility evaluation of infertile women: a committee opinion. Fertility and Sterility. 2021;116(5):1255–1265. Elsevier.
4. Broer S.L., Broekmans F.J.M., Laven J.S.E., Fauser B.C.J.M. Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications. Human Reproduction Update. 2014;20(5):688–701. Oxford University Press.

5. Practice Committee of the American Society for Reproductive Medicine. Diagnostic evaluation of the infertile male: a committee opinion. Fertility and Sterility. 2021;115(1):54–61. Elsevier.

6. Alpha Scientists in Reproductive Medicine and ESHRE Special Interest Group of Embryology. The Vienna consensus: report of an expert meeting on the development of ART laboratory performance indicators. Human Reproduction Open. 2017;2017(2). Oxford University Press.

7. Zegers-Hochschild F., Adamson G.D., Dyer S., Racowsky C., de Mouzon J., Sokol R., et al. The International Glossary on Infertility and Fertility Care, 2017. Fertility and Sterility. 2017;108(3):393–406. Elsevier.

8. Ministry of Health of the Republic of Uzbekistan. Order No. 106 of 14 January 2020 approving the Regulation on the Procedure for Using Assisted Reproductive Technologies. Registered by the Ministry of Justice on 6 February 2020, registration No. 3217. Tashkent: Ministry of Health of the Republic of Uzbekistan; 2020.

9. President of the Republic of Uzbekistan. Resolution No. PQ-296 of 8 September 2023 on measures to protect maternal and child health and strengthen reproductive health. Tashkent: Government of the Republic of Uzbekistan; 2023.

10. Sunkara S.K., Rittenberg V., Raine-Fenning N., Bhattacharya S., Zamora J., Coomarasamy A. Association between the number of eggs and live birth in IVF treatment: an analysis of 400,135 treatment cycles. Human Reproduction. 2011;26(7):1768–1774. Oxford University Press.